ARCHIVES

1. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and
psychopathology. World psychiatry. 2014 Feb;13(1):28-35.
2. Insel TR. Rethinking schizophrenia. Nature. 2010 Nov 11;468(7321):187-93.
3. Berk M, Forbes M, Narayanaswamy J. The history of biomarkers in psychiatry: lessons learned, lessons forgotten, lessons rediscovered.
The British Journal of Psychiatry. 2025 Jan 15:1-2.
4. García-Gutiérrez MS, Navarrete F, Sala F, Gasparyan A, Austrich-Olivares A, Manzanares J. Biomarkers in psychiatry: concept,
definition, types and relevance to the clinical reality. Frontiers in psychiatry. 2020 May 15;11:432.
5. Trubalski M, Markiewicz R, Markiewicz-Gospodarek A, Kalisz G, Łoza B, Szymańczyk S. Metabolic Plasticity in Schizophrenia:
Clinical Rehabilitation Meets LC–MS Metabolomics and Neurofeedback. International Journal of Molecular Sciences. 2025 Dec
29;27(1):380.
6. Chu H, Zhu H, Ma J, Jiang Y, Cui C, Yan X, Li Q, Zhang X, Chen D, Li X, Li R. Mitochondrial Dysfunction and Metabolic Indicators
in Patients with Drug-Naive First-Episode Schizophrenia: A Case-Control Study. Neuropsychiatric Disease and Treatment. 2024 Dec
31:2433-42.
7. Chouinard VA, Du F, Chen X, Tusuzian E, Ren B, Anderson J, Cuklanz K, Feizi W, Zhou S, Weerasekera A, Cohen BM. Cognitive
impairment in psychotic disorders is associated with brain reductive stress and impaired energy metabolism as measured by 31P
magnetic resonance spectroscopy. Schizophrenia Bulletin. 2025 Jan 27:sbaf003.
8. Yao G, Zeng J, Huang Y, Lu H, Ping J, Wan J, Jiang T, Deng F, Li C, Liu X, Tang C. Discovery of biological markers for schizophrenia
based on metabolomics: a systematic review. Frontiers in Psychiatry. 2025 Mar 28;16:1540260.
9. Zhao H, Zhu G, Zhu T, Ding B, Xu A, Gao S, Chao Y, Li N, Chen Y, Wang Z, Jie Y. Gut microbiome and metabolism alterations in
schizophrenia with metabolic syndrome severity. BMC psychiatry. 2024 Jul 24;24(1):529.
10. Xing M, Gao H, Yao L, Wang L, Zhang C, Zhu L, Cui D. Profiles and diagnostic value of intestinal microbiota in schizophrenia patients
with metabolic syndrome. Frontiers in Endocrinology. 2023 Jul 27;14:1190954.
11. Liu S, Zhang L, Fan X, Wang G, Liu Q, Yang Y, Shao M, Song M, Li W, Lv L, Su X. Lactate levels in the brain and blood of
schizophrenia patients: a systematic review and meta-analysis. Schizophrenia Research. 2024 Feb 1;264:29-38.
12. Zhou M, Li X, Yu W, Lin L, Liang Y, Lu J. MS analysis of the plasma metabolome reveals major changes of amino acid and energy
metabolism for early-onset schizophrenia. American Journal of Translational Research. 2024 Nov 15;16(11):6423.
13. Cui G, Qing Y, Li M, Sun L, Zhang J, Feng L, Li J, Chen T, Wang J, Wan C. Salivary metabolomics reveals that metabolic alterations
precede the onset of schizophrenia. Journal of Proteome Research. 2021 Oct 7;20(11):5010-23.
14. Messinis A, Panteli E, Paraskevopoulou A, Zymarikopoulou AK, Filiou MD. Altered lipidomics biosignatures in schizophrenia: A
systematic review. Schizophrenia Research. 2024 Sep 1;271:380-90.
15. Wu S, Panganiban KJ, Lee J, Li D, Smith EC, Maksyutynska K, Humber B, Ahmed T, Agarwal SM, Ward K, Hahn M. Peripheral lipid
signatures, metabolic dysfunction, and pathophysiology in schizophrenia spectrum disorders. Metabolites. 2024 Aug 28;14(9):475.
16. Xiu M, Fan Y, Liu Q, Chen S, Wu F, Zhang X. Glucose metabolism, hippocampal subfields and cognition in first-episode and never-
treated schizophrenia. International journal of clinical and health psychology. 2023 Oct 1;23(4):100402.
17. Kancsev A, Virág-Tulassay EÉ, Engh MA, Kiss-Dala S, Horváth AA, Hegyi P, Kéri S. Glucose homeostasis and cognitive functions in
schizophrenia: a systematic review and meta-analysis. Scientific Reports. 2025 Jul 2;15(1):22898.
18. Zhang S, Luo M, Kuai X, Li X, Gao T, Dong Y, Lu C, Zhuo K, Xiang Q, Liu D. Serum lipid metabolic characteristics and potential
biomarkers in first-episode schizophrenia. BMC psychiatry. 2025 Dec;25(1):1124.
19. Zheng Y, Cai X, Wang D, Chen X, Wang T, Xie Y, Li H, Wang T, He Y, Li J, Li J. Exploring the relationship between lipid metabolism
and cognition in individuals living with stable-phase Schizophrenia: a small cross-sectional study using Olink proteomics analysis.
BMC psychiatry. 2024 Sep 3;24(1):593.
20. Nieto RR, Carrasco A, Corral S, Castillo R, Gaspar PA, Bustamante ML, Silva H. BDNF as a biomarker of cognition in
schizophrenia/psychosis: an updated review. Frontiers in psychiatry. 2021 Jun 16;12:662407.
21. Dai S, Long Y, Xiao J, Wang Y, Wang X, Shao P, Huang M, Xu Y, Liu F, Tang Y, Xu X. A comprehensive metabolomic and lipidomic
study of olanzapine in the treatment of first-episode schizophrenia. Asian Journal of Psychiatry. 2025 Mar 1;105:104387.
22. Marino C, Zhang S, De Simone G, Grimaldi M, Di Maio A, Iasevoli F, Errico F, D’Ursi AM, de Bartolomeis A, Usiello A. Untargeted
1H NMR-based metabolomics unveils distinct circulating biochemical signatures between treatment-resistant and non-treatment-
resistant schizophrenia patients: a pilot study. Translational Psychiatry. 2026 Feb 223. Khoodoruth MA, Hussain T, Ouanes S, Khoodoruth NW, Hmissi A, Lachica Jr SL, Bankur MN, Khan AW, Makki MS, Khan YS,
Currie J. Peripheral inflammatory and metabolic markers as potential biomarkers in treatment-resistant schizophrenia: Insights from a
Qatari Cohort. Psychiatry Research. 2025 Feb 1;344:116307.
24. Mohib MM, Uddin MB, Rahman MM, Tirumalasetty MB, Al-Amin MM, Shimu SJ, Alam MF, Arbee S, Munmun AR, Akhtar A,
Mohiuddin MS. Dysregulated oxidative stress pathways in schizophrenia: integrating single-cell transcriptomic and human biomarker
evidence. Psychiatry International. 2025 Sep 3;6(3):104.
25. Zhang K, Zou L, Cai Y. Progress in the study of oxidative stress damage in patients with schizophrenia: challenges and opportunities.
Frontiers in Psychiatry. 2025 Feb 21;16:1505397.
26. Soheilipour A, Rajabi F, Maracy MR, Salimi H. Investigating the Effect of N-Acetyl Cysteine on Positive, Negative, and Cognitive
Symptoms of Patients with Schizophrenia: A Clinical Trial.
27. Krzyściak W, Bystrowska B, Karcz P, Chrzan R, Bryll A, Turek A, Mazur P, Śmierciak N, Szwajca M, Donicz P, Furman K. Association
of blood metabolomics biomarkers with brain metabolites and patient-reported outcomes as a new approach in individualized diagnosis
of schizophrenia. International journal of molecular sciences. 2024 Feb 15;25(4):2294.
28. Kogler L, Wang R, Luther T, Hofer A, Frajo-Apor B, Derntl B. Cortisol in schizophrenia spectrum disorders: A comprehensive meta-
analysis. Frontiers in Neuroendocrinology. 2025 Apr 1;77:101186.
29. Kruse AO, Bustillo JR. Glutamatergic dysfunction in Schizophrenia. Translational Psychiatry. 2022 Dec 3;12(1):500.
30. Hong F, Chen Q, Luo X, Xie S, Wei Y, Li X, Li K, Lebeau B, Ling C, Dao F, Lin H. A multi-omics integration framework with
automated machine learning identifies peripheral immune-coagulation biomarkers for schizophrenia risk stratification. International
Journal of Molecular Sciences. 2025 Aug 7;26(15):7640.
31. Han S, Li Y, Gao J. Peripheral blood microRNAs as biomarkers of schizophrenia: expectations from a meta-analysis that combines
deep learning methods. The World Journal of Biological Psychiatry. 2024 Jan 2;25(1):65-81.
32. Wang M, Zhao SW, Wu D, Zhang YH, Han YK, Zhao K, Qi T, Liu Y, Cui LB, Wei Y. Transcriptomic and neuroimaging data integration
enhances machine learning classification of schizophrenia. Psychoradiology. 2024;4:kkae005.
33. Ke PF, Xiong DS, Li JH, Pan ZL, Zhou J, Li SJ, Song J, Chen XY, Li GX, Chen J, Li XB. An integrated machine learning framework
for a discriminative analysis of schizophrenia using multi-biological data. Scientific reports. 2021 Jul 19;11(1):14636.
34. Liu M, Du X, Xue K, Gao Y, Cao X, Li J, Liu S. Targeted metabolomics study on peripheral blood neurotransmitters in early-onset
schizophrenia. Journal of Translational Medicine. 2025 Nov 7;23(1):1238.
35. Adly NM, Khalifa D, Abdel-Ghany S, Sabit H. MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in
schizophrenia. Journal of Neural Transmission. 2025 Aug 8:1-22.
36. Eskandar K. The gut–brain axis in depression, anxiety, and schizophrenia: a scoping review of mechanisms, biomarkers, and therapeutic
implications. Middle East Current Psychiatry. 2025 Dec;32(1):1-21.
37. Xu L, Yu P, Yang H, Huang C, Sun W, Zhang X, Tang X. Altered serum glutathione disulfide levels in acute relapsed schizophrenia
are associated with clinical symptoms and response to electroconvulsive therapy. BMC psychiatry. 2025 Mar 14;25(1):242.
38. Jiang F, Jin T, Yang Q, Wang P, Ji L, Ma X, Zhang C, Tian Q, Zhang X. Abnormal plasma oxidative stress markers in first-episode
schizophrenia and associations with clinical symptoms and cognitive function. Schizophrenia. 2026 Jan 10.
39. Więdłocha M, Zborowska N, Marcinowicz P, Dębowska W, Dębowska M, Zalewska A, Maciejczyk M, Waszkiewicz N, Szulc A.
Oxidative stress biomarkers among schizophrenia inpatients. Brain sciences. 2023 Mar 14;13(3):490.
40. Chen L, Li W, Mo D, Meng X, Yao L, Zhang X, Liu H. Comprehensive Analysis of the Microbiome and Metabolome: Unveiling
Interactions Between Intestinal Flora and Metabolites in Schizophrenia. Neuropsychiatric Disease and Treatment. 2025 Dec 31:1955-
71.
41. Konjevod M, Sáiz J, Bordoy L, Strac DS, Taha AY, Lanceros-Méndez S, Alonso RM. Validated metabolomic biomarkers in psychiatric
disorders: a narrative review. Molecular Medicine. 2025 Jul 9;31(1):254.
42. Malik K, Runtuk KS, Amir N, Nasrun MW, Sadikin M, Hardiany NS, Sadikin AH, Sirait SP. Comparing Metabolic Syndrome
Parameters, Oxidative Stress, Cellular Metabolism, and Gene Polymorphism between People with Schizophrenia and Healthy Controls.
Frontiers in Psychiatry.;17:1715991.
43. Galińska-Skok B, Waszkiewicz N. Markers of schizophrenia—a critical narrative update. Journal of Clinical Medicine. 2022 Jul
7;11(14):3964.
44. Okamoto N, Ikenouchi A, Watanabe K, Igata R, Fujii R, Yoshimura R. A metabolomics study of serum in hospitalized patients with
chronic schizophrenia. Frontiers in psychiatry. 2021 Dec 15;12:763547.
45. Zaki JK, Lago SG, Rustogi N, Gangadin SS, Benacek J, Van Rees GF, Haenisch F, Broek JA, Suarez-Pinilla P, Ruland T, Auyeung B.
Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic
markers. Translational Psychiatry. 2022 Oct 30;12(1):457.
46. Deng H, He L, Wang C, Zhang T, Guo H, Zhang H, Song Y, Chen B. Altered gut microbiota and its metabolites correlate with plasma
cytokines in schizophrenia inpatients with aggression. BMC psychiatry. 2022 Sep 27;22(1):629.
47. Meyer JM, Correll CU. Increased metabolic potential, efficacy, and safety of emerging treatments in schizophrenia. CNS drugs. 2023
Jul;37(7):545-70.
48. Shi L, Ju P, Meng X, Wang Z, Yao L, Zheng M, Cheng X, Li J, Yu T, Xia Q, Yan J. Intricate role of intestinal microbe and metabolite
in schizophrenia. BMC psychiatry. 2023 Nov 17;23(1):856.
49. Wang Z, Wang Y, Jiang H, Chen L, Zhang X. Identification of Plasma Biomarkers in Untreated Schizophrenia Patients Using
Untargeted Lipid Metabolomics. Neuropsychiatric Disease and Treatment. 2025 Dec 31:2721-32.
50. Ogur YS, Kaya AE, Ogur NB, Akturk BE. Diagnosing schizophrenia with routine blood tests: a comparative analysis of machine
learning algorithms. Frontiers in Psychiatry. 2025 Aug 19;16:1630922